TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Clinical resolution of acute otitis media
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulsatility index of uterine arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Resistance index of uterine arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: median intestinal wet weight absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: annual decline in lung function (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean mQoL ratings
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ESM daily life measures
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Accuracy of computed tomography in diagnosing acute appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of depression
Endpoint domain: Adverse events/effects
Primary endpoint: myocardial viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: global LV function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: regional LV function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of no relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in HAM-D retardation subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving remission (HAM-D total score ≤ 7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: smoking cessation effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean quality of life scores related to salivation and xerostomia
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Objective increases in the amounts of saliva produced
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vaginal birth not achieved in 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: caesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: uterine hyperstimulation with changes in fetal heart rate
Endpoint domain: Adverse events/effects
Primary endpoint: Analgesic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pain outcomes
Primary endpoint: Inflammatory markers (WBC, N, CRP, IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rates of obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HAM-A total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAM-A psychic anxiety factor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum melatonin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Core body temperature (CBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total HDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDL2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: oesophageal transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to develop a reactive OraQuick test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of BPAR
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of graft take
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean analgesia consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QoL) score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: NT-pro-BNP levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma B-type natriuretic peptide (BNP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: New York Heart Association functional class
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: frequency of readmission because of worsening of CHF
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CCO2R at PETCO2 of 35 to 50 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of successful communication exchanges about pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of communication acts within a communication exchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rated communication at high difficulty less often
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bacterial counts after surgical scrub
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: root coverage outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of mature dendritic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Production of interferon-gamma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Production of interleukin-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: first-shock success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of reintubation
Endpoint domain: Adverse events/effects
Primary endpoint: Marrow fat content reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of bone resorption marker CTX decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of pin-site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Confidence scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Communication scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: clinical outcome measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LII (Linear Interincisal Measurement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in infraorbital hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: weekly weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shrinkage of the graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invasive Ipsilateral Breast Tumor Recurrence (I-IBTR)
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of breast cancer death
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in CSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in IgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in histamine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiovascular death or CHF hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Access to health services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median trough serum drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean surgical time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time from diagnosis to operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feeling of control over the disease
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Age-normalized z scores increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glycosylated hemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of participants reporting symptomatic, glucose-confirmed, and nocturnal hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of heart failure (HF)
Endpoint domain: Mortality/survival
Primary endpoint: ETGUG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived understanding of informed consent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of days drank alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: typical number of drinks consumed per drinking day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of days consuming six or more drinks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manic episodes improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mean total YMRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in CGI‐BP mania score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in CGI‐BP overall score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily mean pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burning sensation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient compliance preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Extent of ASIPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: von Willebrand factor binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: P-selectin expression on platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ctemp elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal cytokine levels (interleukin‐5 and ‐8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement of related disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MASI score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA(1c) <or=7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nocturnal hypoglycemia rates
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Snellen visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreases in triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in high-density lipoprotein (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serious adverse event frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Number of CD68 positive cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of COX-2 positive cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of degranulated mast cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: any allogeneic transfusion
Endpoint domain: Adverse events/effects
Primary endpoint: Inhibition of thromboxane production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nitric oxide production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PaO2/FIO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Days of ventilatory support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: systolic and diastolic blood pressure and heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of detecting potential malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of detecting potential malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Average number of attendees
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Admission temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reconvalescence time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean area under the effect curve after administration of SLV317
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum antagonizing effect of SLV317
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-year freedom from progression (FFP) rate
Endpoint domain: Mortality/survival
Primary endpoint: Decrease of pulmonary vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SIA magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flattening effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: deviation from intended length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Eyelid oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Conjunctival injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Lower-limb maximal strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bone quality parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of illness threat
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Up-to-date Pap screenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with community integration
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Stroke-specific health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to Recurrence (TTR)
Endpoint domain: Mortality/survival
Primary endpoint: sense of meaning in life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: perception of body image
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average number of days requiring antiasthma drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom scores for cough, wheeze, and breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaO2 levels during TLV and OLV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Brunnstrom stages improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl‐Meyer upper extremity score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Box&Block Test score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of target identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time required for target identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean error distances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median felodipine area under the plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum concentration of felodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inspiratory occlusion pressure at 100 ms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of heparin residual
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of total impairment of blood coagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of excessive bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum uric acid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 2-year locoregional recurrence free rate
Endpoint domain: Mortality/survival
Primary endpoint: cumulative 2-year Radiation Therapy Oncology Group grade 3/4 toxicity rate
Endpoint domain: Adverse events/effects
Primary endpoint: Reversal of right ventricular dysfunction (RVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decreased systolic pulmonary artery pressure (SPAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Failure rate of resin composite restorations
Endpoint domain: Mortality/survival
Primary endpoint: Antibody positive rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean titer (GMT) of antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody protective rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival without hospitalisation
Endpoint domain: Mortality/survival
Primary endpoint: Adherence in the biofeedback group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sustained fall in St George's Respiratory Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for postoperative mechanical ventilation
Endpoint domain: Adverse events/effects
Primary endpoint: Waking EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visit to emergency department
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 1-RM knee extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-RM knee flexion strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical jump performance (SJ and CMJ height)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in width of keratinized tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Exercise adherence
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: improving asthma quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: reductions in anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Five-year progression-free survival (PCS)
Endpoint domain: Mortality/survival
Primary endpoint: Five-year local recurrence (LR) rate
Endpoint domain: Mortality/survival
Primary endpoint: modified-Rankin-score at day 90 poststroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of cervical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of radicular pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Deep vein thrombosis occurrence
Endpoint domain: Mortality/survival
Primary endpoint: cocaine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HbA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Minimum Erythemal Dose (MED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Net temple elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Relative proportion of PMN cells showing phagocytic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative level of NK cell tumor killing activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: No microbial growth from swab cultures
Endpoint domain: Adverse events/effects
Primary endpoint: rest pain 2 h after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activity pain 12 h post operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quadriceps strength 24 h and 48 h after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes